| 9th May 2025 7:00 am |
RNS |
Imfinzi improved DFS in early bladder cancer |
| 7th May 2025 7:30 am |
RNS |
Enhertu improved pCR in early-stage breast cancer |
| 6th May 2025 7:00 am |
RNS |
Calquence combination approved in EU for 1L MCL |
| 2nd May 2025 7:00 am |
RNS |
Breztri met primary endpoints in Ph3 asthma trials |
| 1st May 2025 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 1st May 2025 3:00 pm |
RNS |
Total Voting Rights |
| 29th Apr 2025 7:10 am |
RNS |
Fixed-duration Calquence recommended in EU for CLL |
| 29th Apr 2025 7:05 am |
RNS |
Update on CAPItello-280 Phase III trial |
| 29th Apr 2025 7:00 am |
RNS |
1st Quarter Results |
| 22nd Apr 2025 7:00 am |
RNS |
Enhertu combination improved PFS in 1L HER2+ mBC |
| 11th Apr 2025 5:30 pm |
RNS |
Result of AGM |
| 4th Apr 2025 7:05 am |
RNS |
Imfinzi approved in EU for AEGEAN |
| 4th Apr 2025 7:00 am |
RNS |
Enhertu approved in EU in post-ET breast cancer |
| 1st Apr 2025 3:00 pm |
RNS |
Total Voting Rights |
| 31st Mar 2025 7:05 am |
RNS |
Calquence recommended for EU approval in 1L MCL |
| 31st Mar 2025 7:00 am |
RNS |
Imfinzi approved in the US for bladder cancer |
| 21st Mar 2025 10:58 am |
RNS |
AZN invests $2.5bn in Beijing R&D & manufacturing |
| 17th Mar 2025 7:10 am |
RNS |
Eneboparatide Phase III trial met primary endpoint |
| 17th Mar 2025 7:05 am |
RNS |
Imfinzi approved in EU for limited-stage SCLC |
| 17th Mar 2025 7:00 am |
RNS |
AstraZeneca to acquire EsoBiotec |
| 12th Mar 2025 6:00 pm |
RNS |
Holding(s) in Company |
| 7th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 7th Mar 2025 11:00 am |
RNS |
Notice of AGM |
| 7th Mar 2025 7:00 am |
RNS |
Imfinzi improved EFS in early-stage gastric cancer |
| 6th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 5th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 3rd Mar 2025 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Mar 2025 7:00 am |
RNS |
Imfinzi recommended for EU approval for AEGEAN |
| 28th Feb 2025 1:00 pm |
RNS |
Enhertu recommended in EU in post-ET breast cancer |
| 26th Feb 2025 7:00 am |
RNS |
Camizestrant improved PFS in 1L HR+ breast cancer |
| 19th Feb 2025 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 18th Feb 2025 2:00 pm |
RNS |
Holding(s) in Company |
| 18th Feb 2025 11:00 am |
RNS |
Annual Financial Report |
| 18th Feb 2025 7:00 am |
RNS |
Directorate Change |
| 6th Feb 2025 7:00 am |
RNS |
Final Results |
| 3rd Feb 2025 5:00 pm |
RNS |
Total Voting Rights |
| 3rd Feb 2025 7:00 am |
RNS |
Imfinzi recommended for EU approval for LS-SCLC |
| 28th Jan 2025 7:00 am |
RNS |
Enhertu approved in US for breast cancer post ET |
| 20th Jan 2025 7:00 am |
RNS |
Dato-DXd approved in US for HR+ breast cancer |
| 17th Jan 2025 7:00 am |
RNS |
Calquence combination approved in US for 1L MCL |
